Client News
OKYO Pharma Limited: Grant of options – Director dealingsLondon, 1 September, 2021 – OKYO Pharma Limited (LSE: OKYO) (“OKYO” or the “Company”), the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce, announces that the board of directors of the Company (the “Board” or “Directors”), with Mr Brancaccio absenting himself on grounds of interest, has awarded the following options on 31 August 2021.
(a) Gary Jacob
Mr Jacob has been awarded options to acquire 13,000,000 ordinary shares in the capital of the Company. The options are exercisable at a price of 4.9 pence per share (being the mid-market closing price of the Company’s shares traded on the LSE on 31 August 2021). The options will vest in equal tranches over four years beginning on the date of grant.
Keeren Shah
Ms Shah has been awarded options to acquire 500,000 ordinary shares in the capital of the Company. The options are exercisable at a price of 4.9 pence per share (being the mid-market closing price of the Company’s shares traded on the LSE on 31 August 2021). The options will vest in equal tranches over four years beginning on the date of grant.
(b) John Brancaccio
Mr Brancaccio has been awarded options to acquire 900,000 ordinary shares in the capital of the Company. The options are exercisable at a price of 4.9 pence per share (being the mid-market closing price of the Company’s shares traded on the LSE on 31 August 2021). The options will vest in equal tranches over four years beginning on the date of grant.
https://www.londonstockexchange.com/news-article/OKYO/director-pdmr-shareholding/15118045
OPEN AN ACCOUNT
If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.
CLIENT AREA
Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.